Platform deals on the rise in pharma and healthcare: Rothschild & Co. MD Subhakanta Bal
“If you think about private equity, especially the larger funds, I think the concept around platform building makes a lot of sense for several reasons,” said Bal. First off is the scale benefit. Second, “scope to eke out efficiencies on procurement, supply chain, and overheads,” he said. There is also the ability to invest in capability, including technology, and lastly, “from an exit perspective, especially for public markets, where scale has its own premium or attractiveness”.
